FMP
Angion Biomedica Corp.
ANGN
NASDAQ
Inactive Equity
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
1 USD
0 (0%)
About
ceo
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.angion.com
exchange
NASDAQ
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
CIK
0001601485
ISIN
US03476J1079
CUSIP
03476J107
Address
51 Charles Lindbergh Boulevard
Phone
415 655 4899
Country
US
Employee
3
IPO Date
Feb 5, 2021
Summary
CIK
0001601485
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
03476J107
ISIN
US03476J1079
Country
US
Price
1
Beta
0.6
Volume Avg.
9.77k
Market Cap
30.11M
Shares
-
52-Week
1.0-20.4
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.1
P/B
-
Website
https://www.angion.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ANGN News
It looks like there's no news available.
